Complications Post-Endovascular Abdominal Aortic Aneurysm Repair in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Ann Vasc SurgMay 12, 2026 (epub)
Clinical ResearchVascular SurgeryCardiology

Eman Ashraf Adly Aly Otify, I Sanders, J Borucki et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined complications following endovascular abdominal aortic aneurysm (AAA) repair in patients with diabetes mellitus (DM) compared to those without. The study included 90,347 controls and 23,988 DM patients. It found that patients with DM had a lower reintervention rate (9.51% vs 11.92%; OR 0.82, P < 0.001) and reduced rates of sac enlargement and conversion to open surgery.

Key findings

  • Patients with DM had a lower reintervention rate of 9.51% compared to 11.92% in controls (OR 0.82, P < 0.001).
  • The rate of sac enlargement post-repair was lower in DM patients at 9.05% versus 10.38% in controls (OR 0.86, P = 0.005).
  • Conversion to open surgery was reduced in DM patients at 2.11% compared to 3.12% in controls (OR 0.80, P = 0.023).
  • No significant differences were found in overall, type I, or type II endoleaks between the groups.

Why it matters

Understanding the differences in complication rates post-AAA repair in diabetic patients can inform clinical decision-making and risk assessment, potentially leading to improved patient outcomes in this high-risk population.

Source

PubMed · PMID 42119724

Published in Ann Vasc Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Vascular Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.